Signifiant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge

Thrombosis and Haemostasis

Volumn 114, Issue 1, 2015, Pages 7-8

  Serebruany, Victor ^a   Cherepanov, Vasily ^a   Dukhanin, Alexander ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; MORPHINE; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT;

ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL (TOPIC); CORONARY REPERFUSION; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; HEART ARREST; HUMAN; LUNG EDEMA; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCIENTIFIC LITERATURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; EMERGENCY HEALTH SERVICE; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; RISK FACTOR; TIME;

ADENOSINE; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; EMERGENCY MEDICAL SERVICES; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84934783769     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0936     Document Type: Article

References (10)

1. Montalescot G, van 't Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027.
2. Wallentin L, Becker RC, Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
3. Serebruany VL. Paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
4. Kunadian V, James SK, Wojdyla DM, et al. Angiographic Outcomes in the PLATO Trial Platelet Inhibition and Patient Outcomes. JACC Cardiovasc Interv 2013; 6: 671-683.
5. The FDA ticagrelor Secondary Review. Available for download at http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM220192.pdf. (Assessed October 8th, 2014).
6. The FDA Ticagrelor Review of Complete Response. Available for download at: http://www.ac cessdata.fda.gov/drugsatfda_docs/ nda/2011/022433Orig1s000TOC.cfm (Assessed October 8th, 2014).
7. Montalescot G, van 't Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; http://dx.doi.org/10.1056/NEJMoa1407024.
8. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013; 368: 1303-1313.
9. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-942.
10. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437-444.